This recent designation marks the seventh issued patent to cover Indiplon. It will provide Neurocrine with patent exclusivity for Indiplon Polymorph Form III, a novel form of the drug made up of a different crystal structure to the original.
Indiplon is a unique non-narcotic, non-benzodiazepine agent that acts on a specific site of the GABA-A receptor. Indiplon has been shown to bind selectively to the specific subtype of GABA-A receptors within the brain believed to be responsible for promoting sleep. Indiplon was developed to address different types of sleep problems.
The company is currently awaiting approval of Indiplon as an insomnia treatment following a recent notice from the FDA accepting the product for review. If accepted, Indiplon will be co-promoted in the US with Pfizer.